Alnylam president hints at spinoff, new pacts

Xconomy's Ryan McBride writes that Alnylam President Barry Green has dropped a few fresh hints about the closely-watched company's future direction--including a possible spin-off similar to the one that created Regulus Therapeutics. Two years ago Alnylam and Isis created Regulus as a spin-off aimed at developing microRNA therapies.

Green mentioned a "Regulus-like" spinoff at the MassBio Investors Forum in Boston yesterday. But he later declined to detail to McBride exactly what he had in mind. Alnylam CEO John Maraganore told Xconomy earlier this year that it possessed a number of technologies with spinoff potential. Green also told the crowd to expect a couple of major alliances in the near future.

"While this mysterious "Regulus-like" deal now exists as speculation," notes McBride, "it could be interesting to see how Alnylam finds new ways to reap value from its existing portfolio of drug candidates or RNAi patents."

- read the story from Xconomy

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.